These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Transforming growth factor 15 increased in severe aplastic anemia patients. Shao Y, Wang H, Liu C, Cao Q, Fu R, Wang H, Wang T, Qi W, Shao Z. Hematology; 2017 Oct 20; 22(9):548-553. PubMed ID: 28385068 [Abstract] [Full Text] [Related]
8. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure. Przybyłowski P, Wasilewski G, Bachorzewska-Gajewska H, Golabek K, Dobrzycki S, Małyszko J. Transplant Proc; 2014 Oct 20; 46(8):2852-5. PubMed ID: 25380934 [Abstract] [Full Text] [Related]
10. Iron Status and Inflammation in Early Stages of Chronic Kidney Disease. Łukaszyk E, Łukaszyk M, Koc-Żórawska E, Tobolczyk J, Bodzenta-Łukaszyk A, Małyszko J. Kidney Blood Press Res; 2015 Oct 20; 40(4):366-73. PubMed ID: 26160488 [Abstract] [Full Text] [Related]
13. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications. Tantawy AA, Adly AA, Ismail EA, Darwish YW, Ali Zedan M. Blood Cells Mol Dis; 2014 Dec 20; 53(4):189-93. PubMed ID: 25065856 [Abstract] [Full Text] [Related]
14. GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease. Farag NM, Mousa M, Elsayed E, Ismeil A. Ital J Pediatr; 2023 Aug 30; 49(1):106. PubMed ID: 37649102 [Abstract] [Full Text] [Related]
15. The relationship of Prohepcidin levels with anemia and inflammatory markers in non-diabetic uremic patients: a controlled study. Aydin Z, Gursu M, Karadag S, Uzun S, Sumnu A, Doventas Y, Ozturk S, Kazancioglu R. Ren Fail; 2014 Sep 30; 36(8):1253-7. PubMed ID: 25040737 [Abstract] [Full Text] [Related]
16. The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/βthal), correlate with markers of hemolysis, iron burden, coagulation, endothelial dysfunction and pulmonary hypertension. Larissi K, Politou M, Margeli A, Poziopoulos C, Flevari P, Terpos E, Papassotiriou I, Voskaridou E. Blood Cells Mol Dis; 2019 Jul 30; 77():137-141. PubMed ID: 31071550 [Abstract] [Full Text] [Related]
17. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. Shinzato T, Abe K, Furusu A, Harada T, Shinzato K, Miyazaki M, Kohno S. Med Sci Monit; 2008 Sep 30; 14(9):CR431-7. PubMed ID: 18758412 [Abstract] [Full Text] [Related]